Sort
82,697 grants matching “vaccine development”
IGF::OT::IGF R&D-A PHASE I TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A DNA PLASMID BASED VACCINE (WOKVAC) ENCODING EPITOPES DERIVED FROM THREE BREAST CANCER ANTIGENS (IGFBP-2, HER2, AND IGF-IR) IN PAT
$727,469Howard Bailey · University Of Wisconsin-Madison · N01 · FY2015 · CA
A systems biology approach to fingerprint HIV immune defense in Elite Controllers
$727,444Xu Yu · Massachusetts General Hospital · R56 · FY2012 · AI
Project 2: Safety Evaluation of Combination Antiretroviral Intravaginal Rings
$727,419Marc Michael Baum · Oak Crest Institute Of Science · U19 · FY2014 · AI
Mechanisms of MERS-CoV Entry, Cross-species Transmission and Pathogenesis
$727,370Ralph S Baric · Univ Of North Carolina Chapel Hill · R01 · FY2018 · AI
Novel Nanovaccines Against Nicotine Addiction
$727,306Chenming M Zhang · Virginia Polytechnic Inst And St Univ · U01 · FY2014 · DA
Molecular Pharmacology of NKT Cell Agonists
$727,292Luc Teyton · Scripps Research Institute, The · R01 · FY2016 · AI
Molecular Pharmacology of NKT Cell Agonists
$727,292Luc Teyton · Scripps Research Institute, The · R01 · FY2017 · AI
Effects of a Novel, Scalable, and Sustainable Patient Portal Intervention on Diabetes-Related Outcomes: A Pragmatic Randomized Controlled Trial
$727,286William Martinez · Vanderbilt University Medical Center · R01 · FY2024 · DK
A rationally-designed, live-attenuated RSV vaccine for the elderly
$727,278Steffen Mueller · Codagenix, Inc. · R44 · FY2020 · AI
Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal
$727,275Mayumi Nakagawa · Univ Of Arkansas For Med Scis · R01 · FY2023 · CA
Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal
$727,272Mayumi Nakagawa · Univ Of Arkansas For Med Scis · R01 · FY2021 · CA
Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal
$727,264Mayumi Nakagawa · Univ Of Arkansas For Med Scis · R01 · FY2025 · CA
Developmental Exposures to Arsenic: Pneumonia, Immunity, and Microbiomes (DEAPIM)
$727,218Muhammad F Parvez · Columbia University Health Sciences · R01 · FY2024 · ES
Cold Chain-Independent, Needle-Free Mucosal Virosomal Vaccine to Prevent HIV-1 Acquisition at Mucosal Levels
$727,169Ruth Margrit Ruprecht · University Of Louisiana At Lafayette · U19 · FY2019 · AI
Sleep and Vaccine Response in Nurses (SAV-RN)
$727,134Daniel J Taylor · University Of North Texas · R01 · FY2018 · AI
Practices Core
$727,128William Paul Duprex · University Of Pittsburgh At Pittsburgh · UC7 · FY2023 · AI
Biomarker Approach to Screening for the early detection of HPV-related Oropharyngeal Cancer (BASH OPC)
$727,078Anna R Giuliano · H. Lee Moffitt Cancer Ctr & Res Inst · U01 · FY2023 · DE
Dissemination of the Cardiovascular Risk Service (CVRS Live)
$727,008Korey A Kennelty · University Of Iowa · R01 · FY2021 · HL
Evolution and Transmission of Influenza Virus in Natural Human Infection
$726,987Adam Lauring · University Of Michigan At Ann Arbor · R01 · FY2023 · AI
Lead Optimization of DHODH Inhibitors for Malaria
$726,917Margaret A. Phillips · Ut Southwestern Medical Center · R01 · FY2021 · AI
Studies of HCV Infection And HCV-Host interactions
$726,910T. Jake Liang · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2021 · DK
Administrative Core
$726,886David B. Weiner · Wistar Institute · U19 · FY2023 · AI
Understanding pathogen and host determinants of the natural history of N. gonorrhoeae infection
$726,859Joseph A Duncan · Univ Of North Carolina Chapel Hill · R01 · FY2023 · AI
Baltimore Pediatric AIDS Clinical Trials Group
$726,766Johns Hopkins University · U01 · FY2005 · AI
Host Genetic Epidemiology in HIV-1-Discordant African Couples and Other Cohorts
$726,755Richard A Kaslow · University Of Alabama At Birmingham · R01 · FY2008 · AI